Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JS105
- Development stage
- Phase 3
- Lead developer
- Li Ning
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JS105 is an oral small molecule inhibitor targeting PI3K-alpha (PIK3CA). **Mechanism of Action** JS105 selectively targets, binds to, and inhibits PIK3CA in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway. This pathway is frequently dysregulated in various cancers, particularly breast cancer, where PIK3CA mutations are present in approximately 40% of HR+/HER2- breast cancer patients.
- Other names
- RP903RP-903RP 903JS-105JS105JS 105
02
Targets
PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on JS105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JS105.